{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.3","value":"1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"HDL Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.4","value":"1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"HDL Week 35 n=41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"LDL Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"LDL Week 35 n=41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.7","value":"69.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Total Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.8","value":"68.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Total Week 35 n=41"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"LDL=Low density lipoprotein, HDL=high density llipoprotein and total protein were analyzed by a central laboratory","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide montherapy (0.6 mg bid to 0.9 mg bid) was administered until the biochemical control was achieved and if not achieved, a combination was administered: pasireotide (0.9 mg bid) + cabergoline (0.5 QD to 1 mg QD). Patients were able to add cabergoline at anytime during core and extension","id":"OG000","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Baseline and week 35","title":"LDL, HDL and Total Cholesterol at Week 35","type":"SECONDARY","unitOfMeasure":"mmol/L"}